Beijing Luzhu Biotechnology Co Ltd
02480
Company Profile
Business description
Beijing Luzhu Biotechnology Co., Ltd. is a biotechnology company committed to developing human vaccines and therapeutic biologics to prevent and control infectious diseases and treat cancer and autoimmune diseases. The Group's product pipeline consisted of three clinical-stage product candidates, including its Core Product, LZ901, and six pre-clinical-stage product candidates.
Contact
No. 3 Guangtong Street
Industrial Development Zone, Zhangjiawan Tongzhou District
Beijing
CHNT: +86 1061568561
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
193
Stocks News & Analysis
stocks
Older cohorts the budget losers, not necessarily the ASX listed insurers
Proposed legislation removes health insurance rebates.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,829.50 | 17.30 | 0.20% |
| CAC 40 | 7,987.28 | 0.21 | -0.00% |
| DAX 40 | 24,428.17 | 120.25 | 0.49% |
| Dow JONES (US) | 49,432.74 | 253.38 | -0.51% |
| FTSE 100 | 10,328.53 | 4.78 | 0.05% |
| HKSE | 25,797.85 | 122.67 | 0.48% |
| NASDAQ | 25,765.60 | 325.13 | -1.25% |
| Nikkei 225 | 60,550.59 | 265.36 | -0.44% |
| NZX 50 Index | 12,974.32 | 211.40 | 1.66% |
| S&P 500 | 7,340.87 | 62.18 | -0.84% |
| S&P/ASX 200 | 8,604.70 | 23.10 | 0.27% |
| SSE Composite Index | 4,169.54 | 38.01 | 0.92% |